FDA Device Decisions, May 2025: A Transcatheter Mitral Valve for Severe Annular Calcification, Five-Year Breast Cancer Risk Software and Four De Novo Grants
One of FDA's three original PMA approvals in May 2025 went to the Tendyne Transcatheter Mitral Valve System (P240042), a replacement mitral valve delivered by catheter through the apex of the heart. This approval covers mitral valve dysfunction associated with severe mitral annular calcification (MAC) in patients a heart team has judged unsuitable for both surgery and transcatheter edge-to-edge repair.
Among the month's De Novo grants was software that estimates, from a screening mammogram, the probability of a breast cancer diagnosis in the following five years. The classification's special controls require a plan for monitoring performance after launch.
Counting records held in RA Craft Database (decisions through August 31, 2026, tallied October 6), FDA cleared 298 510(k)s in May 2025, granted 4 De Novo requests and approved 3 original PMAs. These counts have not been reconciled with FDA's own figures. The site holds 510(k), De Novo and PMA records from 2015 onward, and counts for past months can change as the data are updated.
Counts by pathway
May 2025 next to the previous month and the same month a year earlier, with records assigned to a month by FDA decision date.
| Pathway | May 2025 | April 2025 | May 2024 |
|---|---|---|---|
| 510(k) | 298 | 281 | 274 |
| De Novo | 4 | 4 | 3 |
| PMA (original) | 3 | 3 | 1 |
| PMA supplement | 176 | 187 | 208 |
Records held in RA Craft Database, decisions through August 31, 2026.
510(k) clearances were 17 more than in April and above May 2024 (274). There were 4 De Novo grants and 3 original PMAs.
The busiest product codes
May's 510(k)s spread across 181 product codes. IYN (system, imaging, pulsed doppler, ultrasonic) led with 13, followed by QIH (automated radiological image processing software) with 11, GEX (powered laser surgical instrument) with 6, and EBF (material, tooth shade, resin), GEI (electrosurgical, cutting & coagulation & accessories) and NHA (abutment, implant, dental, endosseous) with 5 each. A single 510(k) can carry more than one product code, so per-code counts can add up to more than the number of submissions. If your code is on the list, enter it in the Product Code field on Search to see the records sorted by decision date.
De Novo: four classifications
May's four De Novo grants, all Class II, with the classification names and regulation numbers from each Classification Order:
- Teal Wand (DEN240045, Teal Health, Inc.): Device for home collection and transportation of clinical specimens by lay users for infectious disease testing (21 CFR 866.2920)
- ConcizuTrace ELISA (DEN240035, Randox Laboratories Ltd): Non-factor replacement product test system (21 CFR 864.7298)
- Spur Peripheral Retrievable Stent System (DEN240048, Reflow Medical, Inc.): Peripheral temporary and retrievable stent system (21 CFR 870.5110)
- Clairity Allix5 (DEN240047, Clairity, Inc.): Radiological software device to predict future breast cancer risk (21 CFR 892.8500)
"21 CFR" refers to Title 21 of the Code of Federal Regulations, where FDA's regulations are codified.
Teal Wand lets women collect their own vaginal specimens at home or another private setting for an FDA-approved human papillomavirus (HPV) assay. ConcizuTrace ELISA measures concizumab concentration in patients with hemophilia A or B for dose adjustment in line with the drug label. Spur is a retrievable stent used as an adjunct to percutaneous transluminal angioplasty for stenoses in infrapopliteal arteries 2.5 to 4.5 mm in diameter.
Original PMAs: three approvals
- VENTANA MET (SP44) RxDx Assay (P240037, Ventana Medical Systems, Inc.): an immunohistochemistry assay for MET protein in non-squamous non-small cell lung cancer tissue, a companion diagnostic for EMRELIS (telisotuzumab vedotin-tllv) (product code SER)
- EndoForce Connector for Endovascular Venous Anastomosis (P240004, Phraxis Inc.): a covered stent that attaches a hemodialysis graft to an upper-arm vein from inside the vessel instead of a sutured anastomosis (SEQ)
- Tendyne Transcatheter Mitral Valve System (P240042, Abbott Medical): transapical transcatheter mitral valve replacement (NPU)
May also brought 176 PMA supplements, which cover changes to already approved PMA devices among other things.
Three devices worth a closer read
1. Tendyne Transcatheter Mitral Valve System (P240042, PMA). Porcine pericardial leaflets on a nitinol frame, delivered through the apex and anchored by a tether to a pad on the outside of the heart. The pivotal evidence came from the severe MAC cohort of the SUMMIT trial (103 patients): 60.4% were free of all-cause death and heart failure hospitalization at 12 months, against a performance goal of 43.0%. According to the Summary of Safety and Effectiveness Data (SSED) that FDA published with the approval, the device received Breakthrough Device designation in 2021. The conditions of approval include following the trial cohort to five years and following at least 200 real-world patients for five years through the STS/ACC TVT Registry.
2. Clairity Allix5 (DEN240047, De Novo). Software that estimates, from a bilateral screening mammogram, the probability that the person will be diagnosed with breast cancer within five years. It does not diagnose or detect breast cancer, and its output is meant to be considered after the radiologist has finished reading the mammogram. One of its four special controls is a postmarket performance management plan: monitoring real-world performance for change, identifying the sources of change and their effect on safety and effectiveness, and telling users the current performance. The labeling must also show current performance, including postmarket data. The Classification Order speaks of models and algorithms but does not use the words AI or machine learning.
3. Teal Wand (DEN240045, De Novo). A woman collects her own vaginal specimen at home or another private setting and ships it dry in an empty vial, for use with an FDA-approved HPV assay validated with the device. Its five special controls first limit the device to specimen types suitable for lay collection, rule out tests for pathogens where lay collection could cause serious harm, and restrict use to validated assays. On top of that, they require data on whether lay users can use the device and understand its labeling.
Compare the three devices
Open P240042, DEN240047 and DEN240045, star (☆) each one, tick "Compare" on all three in My Workspace and press "3 selected for comparison". The comparison table puts their Indications for Use side by side. Before relying on any of this, open "FDA Record" and "Summary PDF" on each record and read the source.
Note: months are assigned by FDA decision date, and counts can change as the data are updated each month.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles